← Back to Search

EBUS-TBNA Diagnostic Procedure for Early-Stage Lung Cancer

N/A
Waitlist Available
Led By George A. Eapen, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient must have proven or suspected non small cell lung cancer (NSCLC) and be clinical Stage I or IIa, according to the 7th edition staging system of the American Joint Commission on Cancer for lung cancer (T1 or T2a, N0 or N1, M0)
Patient must be > 18 years old
Must not have
Patients already scheduled to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression)
Patients malignancy is consistent with well differentiated neuroendocrine (carcinoid) histology
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

Summary

This trial looks at EBUS-TBNA after PET/CT to see if it can help diagnose patients with early stage NSCLC who are being evaluated for SBRT.

Who is the study for?
This trial is for adults over 18 with early-stage non-small cell lung cancer (Stage I or IIa), who haven't had chemotherapy or radiotherapy for this cancer, and are being considered for a precise type of radiation therapy called SBRT. They must have had a PET/CT scan within the last 40 days and provided written consent. Cancer survivors can join if they've been free from active disease for at least five years.Check my eligibility
What is being tested?
The study is testing how well EBUS-TBNA works in diagnosing patients after they've had a PET/CT scan. It aims to improve accuracy in detecting early-stage lung cancer among those evaluated for stereotactic body radiation therapy.See study design
What are the potential side effects?
While not explicitly listed, potential side effects of EBUS-TBNA may include discomfort at the biopsy site, minor bleeding, infection risk, and rarely complications related to sedation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung cancer is in the early stages (Stage I or IIa).
Select...
I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am already scheduled for standard cancer treatments other than at disease progression.
Select...
My cancer is a type of well-differentiated neuroendocrine tumor.
Select...
I have had chemotherapy or radiotherapy for my cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Lymphnode Staging Accuracy

Trial Design

1Treatment groups
Experimental Treatment
Group I: EBUS-TBNAExperimental Treatment1 Intervention
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT. A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) is a minimally invasive procedure used to obtain tissue samples from the lungs and surrounding lymph nodes. This technique is crucial for the accurate diagnosis and staging of lung cancer, particularly non-small cell lung cancer (NSCLC). The tissue samples obtained can be analyzed for molecular markers, which guide targeted therapies such as EGFR tyrosine kinase inhibitors. These targeted therapies work by blocking specific molecules involved in cancer cell growth and survival. Additionally, chemotherapy and radiation therapy are used to kill rapidly dividing cancer cells, while surgery may be employed to remove localized tumors. Understanding these mechanisms is vital for lung cancer patients as it allows for personalized treatment plans that can improve outcomes and potentially extend survival.
Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis.Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,002 Previous Clinical Trials
1,794,129 Total Patients Enrolled
George A. Eapen, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
61 Total Patients Enrolled

Media Library

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) Clinical Trial Eligibility Overview. Trial Name: NCT02719847 — N/A
Lung Cancer Research Study Groups: EBUS-TBNA
Lung Cancer Clinical Trial 2023: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) Highlights & Side Effects. Trial Name: NCT02719847 — N/A
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02719847 — N/A
~25 spots leftby Mar 2026